https://www.selleckchem.com/pr....oducts/Cyclosporin-A
In the present review, different types of nanocarriers, their capability in targeting leukemic cells, and the latest preclinical and clinical data are discussed.Development of a safe and efficacious vaccine against the HIV/AIDS pandemic remains a major scientific goal. We previously described an HIV/AIDS vaccine based on the modified vaccinia virus Ankara (MVA) expressing HIV-1 gp120 and Gag-Pol-Nef (GPN) of clade B (termed MVA-, which showed moderate immunogenicity in phase I prophylactic and therapeutic clinica
Like
Comment
Share
